Related Experiment Videos
Group B streptococcal infections
1Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Insights
Group B Streptococcus (GBS) infections pose risks to pregnant women and infants. New guidelines for intrapartum chemoprophylaxis aim to significantly reduce early-onset GBS infections in newborns.
Area of Science:
- Obstetrics and Gynecology
- Neonatology
- Infectious Diseases
Background:
- Group B streptococcal (GBS) disease is a significant cause of illness in pregnant individuals and newborns.
- Understanding GBS colonization and its link to adverse pregnancy outcomes is crucial.
Purpose of the Study:
- To review recent advancements in managing Group B streptococcal disease in obstetric and neonatal care.
- To discuss the emergence of GBS serotype V and its impact on infant disease.
- To summarize new guidelines for intrapartum chemoprophylaxis.
Main Methods:
- Literature review of recent developments in GBS disease management.
- Analysis of GBS serotype V emergence and late-onset disease impact.
- Summary of proposed intrapartum chemoprophylaxis guidelines.
Main Results:
- GBS colonization is associated with adverse pregnancy outcomes.
- Serotype V is an emerging concern in GBS infections.
- New guidelines for intrapartum chemoprophylaxis are proposed.
- Implementation of guidelines is expected to reduce early-onset GBS infections.
Conclusions:
- Recent developments offer improved strategies for managing GBS disease in pregnancy and infancy.
- Adherence to new chemoprophylaxis guidelines is anticipated to decrease neonatal GBS infections.
Abstract:
Group B streptococcal disease remains a prominent cause of infectious morbidity in pregnant women and their infants. This article highlights recent developments that are relevant for obstetricians, perinatologists, and neonatologists caring for patients with group B streptococcal disease. The morbidity of group B streptococcal infections in pregnancy and the proposed association of colonization with adverse pregnancy outcome is discussed, as is the emergence of serotype V and the impact of late, late-onset disease for infants. Finally, the recently proposed guidelines for intrapartum chemoprophylaxis are summarized. Implementation of the guidelines should have substantial impact on reduction of early-onset group B streptococcal infections in infancy.